Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of ibrexafungerp for the treatment of vulvovaginal candidiasis

Next Previous
X
Search
Trial Profile

Phase 3 study of ibrexafungerp for the treatment of vulvovaginal candidiasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors SCYNEXIS

    • Most Recent Events

    • 20 Jul 2023 According to a SCYNEXIS media release, China National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC) in the Chinese mainland.
    • 20 Sep 2021 New trial record
    • 13 Sep 2021 According to a SCYNEXIS media release, Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) has filed an investigational new drug (IND) application with the National Medical Products Administration (NMPA) to initiate this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top